Table V-QOvarian Cancer. Time to Event Outcome Regression Modeling

StudyDesign/Outcome/ModelCandidate Predictors/Method for Identifying CandidatesUnivariate Results, Variable (p value)Selected Predictors/Methods for Selecting Predictors for Multivariate ModelProportional Hazards Assumption Assessed?/Interactions Considered?Multivariate Model Results, Variable (p value)Discrimination/Validation Methods/ResultsCalibration/Goodness of Fit
9040, Camilleri-Broet et al., 2004RET/PFS, OS/Cox??based on UV
PFS: PS, ascites, residual lesion size, HER2
OS: PS, ascites, residual lesion size, HER2
?PFS:ascites (<0.01), HER2 (0.02)
OS: ascites (0.04), HER2 (0.04)
N?
10820, Bookman et al., 2003
11720, Bowman et al., 2002
13450, Campos et al., 2001
15150, Hengstler et al., 1999
17300, Di Leo et al., 1995RET/TTF, OS/Cox recurs partimaging, tumor grade, residual tumor volume, age, disease sites, tumor responsiveness, p53, HER2TTF: disease detectable on imaging (0.02)
OS: (0.01)
TTF: disease detectable on imaging
OS: same
?TTF: disease detectable on imaging
OS: same

From: Appendix C. Evidence Data Abstraction Tables

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.